Fw: (LML) Skin-related neglected tropical diseases

                    Leprosy Mailing List –  January 26,  2026

 

Ref.:  (LML) Skin-related neglected tropical diseases

From: Ben Naafs, Munnekeburen, the Netherlands

____________________________________________________________________________

 

Dear colleagues,

 

Some time ago the World Health Organization (WHO)  released  an enhanced version of its Skin NTDs App, a valuable tool designed to assist front-line health workers in diagnosing and managing skin-related neglected tropical diseases (skin NTDs). The updated App is available free of charge on both Android and iOS devices.

At least ten of the diseases included in World Health Organization's (WHO) list of neglected tropical diseases can present with manifestations on the skin. These so-called skin NTDs include Buruli ulcer, cutaneous and post-kala azar dermal leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, mycetoma, yaws, chromoblastomycosis and other deep mycoses, and scabies and other ectoparasites. Due to their common manifestations, skin NTDs can be targeted with similar case detection and disease management approaches. Additionally, skin-related NTDs are often associated with lifelong disabilities, stigma and mental health problems. These commonalities, and the frequent co-endemicity of these diseases in many regions, present opportunities for the integration of interventions (InfoNTD)

Implementing the integrated control and management of skin neglected tropical diseases

In the context of skin NTDs, integration is defined as the implementation of two or more activities simultaneously in the same communities in order to optimize the use of limited resources (WHO):

•   = - Skin NTDs are often co-endemic in many countries, districts, and communities. They may have same common manifestations and approaches to detection. Examination of the skin therefore serves as an opportunity to identify multiple conditions in a single intervention and also to improve case detection. For example, post-kala-azar dermal leishmaniasis can be detected during leprosy case detection campaigns, or vice versa.

            - - Skin NTDs are often underreported or are not included in routine surveillance systems. An integrated approach offers opportunities for active screening in communities and in schools.

•    - -Combined activities to control skin NTDs improves understanding of their total related burden and of the need for greater advocacy and optimal and efficient use of human, material and financial resources.

 

Ben

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/0656ebed-6c7a-47d2-b2e8-7853feb205f0n%40googlegroups.com.

Fw: Ref.: (LML) Outcast: A History of Leprosy, Humanity and the Modern World

 

Leprosy Mailing List –  January 25,  2026

 

Ref.:  (LML) Outcast: A History of Leprosy, Humanity and the Modern World

From: Ben Naafs, Munnekeburen, the Netherlands

____________________________________________________________________________

 

 

Dear Pieter,

 

Maria Angela Trindade (Bauru, Brazil), made me aware of an interesting book: "Outcast: A History of Leprosy, Humanity and the Modern World"

By Oliver Basciano,  printed by Faber and Faber, 2025 pp 320, £20·00

 

There is a good review by Anna Greenwood in the Lancet January 2026 (see attached file)

 

With kind regards

Ben

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/6140bb51-5110-4b65-a9e3-66428df8e76fn%40googlegroups.com.

Fw: Ref.: (LML) World Leprosy Day on the last Sunday of January

 

Leprosy Mailing List –  January 22 ,  2026

 

Ref.:  (LML) World Leprosy Day on the last Sunday of January

From: Francesca Gajete, Manila, Philippines

____________________________________________________________________________

 

Dear Pieter,

 

May I share this WHO publication on my mail…kindly help me get this thru LML for our colleagues…

 

Wednesday, 21 January 2026

WHO renews commitment to a leprosy-free world, spotlighting partnership and progress ahead of
World Leprosy Day

https://www.who.int/news/item/21-01-2026-who-renews-commitment-to-a-leprosy-free-world--spotlighting-partnership-and-progress-ahead-of-world-leprosy-day/

Geneva, 21 January 2026 - Access to treatment for leprosy is essential to global efforts to eliminate leprosy, says the World Health Organization (WHO) ahead of World Leprosy Day, to be observed on 25 January.

Leprosy is an infectious disease caused by a type of bacteria, Mycobacterium leprae, and is one of the oldest diseases known to humanity. The disease predominantly affects the skin and peripheral nerves. Left untreated, the disease may cause progressive and permanent disabilities and causes stigma and social isolation However, the disease can be cured with multidrug therapy (MDT).

Efforts to eliminate leprosy have been leading to reductions in the number of new cases in many areas; of the 188 countries, areas or territories that submitted data in 2024, 55 reported zero cases. But still 172 717 new cases were detected worldwide and reported to WHO in the same year.

Many partners, including pharmaceutical companies such as Novartis, have been strong supporters of efforts to eliminate leprosy. WHO has collaborated with Novartis since 2000 to provide MDT and clofazimine, free of cost, to all leprosy patients worldwide. This partnership remains one of the most sustained pharmaceutical donation programmes in global health.

Marking 25 years of partnership, WHO and Novartis have extended a Memorandum of Understanding (MoU) for an additional 5 years (2026−2030). The extension makes provision for continued supply of MDT and also includes funding for procurement and distribution of single dose rifampicin (SDR) for post-exposure prophylaxis (PEP).

"The unwavering commitment of partners like Novartis over the past quarter-century has been foundational to the progress made against leprosy," said Dr Jeremy Farrar, WHO Assistant Director-General for Health Promotion, Disease Prevention and Care. "Their steadfast support in ensuring free access to treatment has helped transform millions of lives and moved us closer to a world free from this ancient disease. This enduring collaboration exemplifies the power of global solidarity in health – a reminder that, together, we can overcome even the oldest and most entrenched health challenges when science, equity, and partnership align."

Availability of free MDT has made it possible to cure the disease, prevent disabilities, mitigate stigma, and has enabled affected individuals to continue working and leading normal lives. Additionally, clofazimine has ensured the treatment of lepra reactions, which are characterized by sudden, severe inflammatory episodes, leading to disabilities, if left untreated.

"Leprosy is one of the oldest infectious diseases known to humanity and combatting it has been part of our company's history since discovering the first effective cure," said Dr Lutz Hegemann, President of Global Health at Novartis. "Over the last 25 years, we have reached millions of patients together with WHO, and we are committed to going further to pursue our vision of a world free of leprosy."

While significant progress has been made, sustaining and building on this momentum requires political commitment, community engagement and continued collaboration and partnership.

The theme for this year's World Leprosy Day is "Leprosy is curable, the real challenge is stigma".

This year also marks the 25^th anniversary of Mr Yohei Sasakawa's work as the WHO Goodwill Ambassador for Leprosy Elimination. He said, "One of the most stubborn challenges that I encounter on my travels is the social stigma attached to leprosy, which can be more problematic than the disease itself, and which can persist beyond the end of treatment. This is particularly true for people who have been left with residual disabilities as a result of leprosy. They may face various forms of discrimination, including forced divorce, lost educational opportunities and unfair dismissal. Even after being cured, they endure the unending pain of social exclusion."

As leprosy is one of the target diseases under the broader umbrella of Neglected Tropical Diseases (NTDs), this work also supports the unified global effort towards a world free of NTDs. Learn more about the collective action and join our campaign on World NTD Day 2026 on 30 January.

Notes for editors

The NTD Roadmap 2021-2030 aims at elimination of leprosy (interruption of transmission). The Global Leprosy Strategy 2021–2030 underpinning the Roadmap, shifts the paradigm beyond the achievement of 'elimination of leprosy as a public health problem' toward interruption of transmission and elimination of leprosy disease. Contact screening along with scale-up of preventive chemotherapy and mitigation of stigma and discrimination constitute key pillars of this strategy. Beyond working to ensure that every person affected by leprosy is detected early and treated promptly, WHO leads efforts to combat the discrimination that persons affected by leprosy too often face.

Related: WHO's work on leprosy

 

The Philippines is now gearing up promotions with our Government facilities, Partner Institutions, Patient Organizations and Partner CSOs for the promotion of WLD 2026 towards the attainment of GPZL 2030.

 

With kind regards,

 

Francesca

 

Dr Francesca Cando Gajete,MHA,FPLS

Member,International   Leprosy Association 

Trustee, Culion Fdtn Inc

Former National Leprosy   Control Program    Manager,Philippines 

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/0851c21b-f07f-4e7c-8246-89c50aae39a9n%40googlegroups.com.

Fw: Ref.: (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

 

 

Leprosy Mailing List –   January 21,  2026

 

Ref.:  (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

From: Cleverson Teixeira Soares, Patrícia Sammarco Rosa and  Bruno de Carvalho Dornelas, Instituto Lauro de Souza Lima, Bauru, Brazil

____________________________________________________________________________

 

Dear Pieter;

 

I hope you are doing fine and wish you a happy 2026!

 

Could you please help us promoting this special issue again?

 

https://www.mdpi.com/si/230126

 

Special Issue Information

Dear Colleagues,

The Special Issue entitled "Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies" aims to present recent research on a wide range of topics related to leprosy, a complex disease that mainly affects people living in developing countries. People exposed to Mycobacterium leprae or Mycobacterium lepromatosis may develop leprosy.

During the course of the disease, reaction phenomena typical of leprosy often occur, known as type 1 (T1R) and type 2 (T2R). These phenomena aggravate the disease and can cause significant and permanent sequelae. Little is known about the pathophysiological mechanisms of leprosy and its reaction phenomena. In addition, factors inherent to the bacilli and its interaction with the human host, such as energy resources and escape mechanisms, are slowly being revealed.

New studies are important to elucidate the pathophysiology of leprosy and, above all, to bring new approaches to the prevention and treatment of leprosy and leprosy reactions. We encourage the submission of clinical, translational, and basic research on leprosy. Some of its focal points include, but are not limited to, the following:

1. Serum or tissue markers that may be related to the diagnosis of the disease and reactional episodes.
2. Therapeutic approaches with commercially known drugs or new drug targets.
3. Clinical studies evaluating the risks of triggering reactional phenomena.
4. Metabolomic, transcriptomic, or proteomic profiles that correlate with the leprosy clinical forms and reactional phenomena.

 

Reviews, original research, and communications will be welcome.

Dr. Cleverson Teixeira Soares
Dr. Patrícia Sammarco Rosa
Dr. Bruno de Carvalho Dornelas
Guest Editors

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/7e46c396-a858-4770-88d4-e62bacfbc47an%40googlegroups.com.

Fw: Ref.: (LML) Deadline approaching: calls for proposals | Save the date: Spring Meeting 2026 | Research spotlight

 

 

Leprosy Mailing List –    January 21,  2026

 

Ref.:  (LML) Deadline approaching: calls for proposals | Save the date: Spring Meeting 2026 | Research spotlight

From: LRI, Amsterdam, the Netherlands

____________________________________________________________________________

Dear colleagues,

 

 

The LRI Secretariat wishes you a happy New Year! We are excited to share this first newsletter of 2026 which features the reminder for the research proposals submission deadline, LRI Spring Meeting dates and a Research spotlight.

 

 

Deadline for research proposal submissions approaching

There is only one week left to submit your Letter of Intent for the following LRI Calls for proposals:

• LRI Flagship grant (projects starting in 2027)
• RESILIENTD grant, in collaboration with Anesvad Foundation (projects starting in 2027)

The submission deadline for both calls is Friday, 23 January, at 17:00 CET. After this time, the portal will close, so please ensure your Letter of Intent is submitted on time. 
 

We look forward to receiving your research ideas. Best of luck to all applicants!

 

Submit your Letter of Intent

 

LRI Spring Meeting 2026 – Save the dates
 

The LRI Spring Meeting is an annual event that brings together researchers from LRI-funded projects, members of the LRI Scientific Review Committee and Steering Committee, as well as LRI partners. More than 35 researchers will present project progress updates and results during this year's edition, which will take place online on 9 and 10 April (afternoons CEST), so be sure to mark your calendars.

The online event is open to everyone interested in leprosy research and is free of charge.

Updates on the event and registration will be provided through our newsletter, website, and LinkedIn channel in due course.

 

 

Research spotlight - Skin Health Programme in a Penitentiary (SHEPP)
 

Under the RESILIENTD grant, the Skin Health Programme in a Penitentiary (SHEPP) launched in 2025 to strengthen the detection and management of skin-related NTDs at Kumasi Central Prison in Ghana. Working closely with incarcerated individuals, prison staff, and affected individuals, the project is co-designing a tailored skin health education programme, conducting screenings, and exploring how social determinants shape disease patterns in prison settings.
 

Initiatives like SHEPP demonstrate how research, community engagement, and system-level action can improve skin health and living conditions for vulnerable populations. However, as highlighted by El País, overcrowded prisons and similar settings continue to face significant challenges—underscoring the urgent need for further research and action.
 

Learn more about the project here and read the El País article here.
 

This work may also inspire new research ideas for the open RESILIENTD call. Congratulations to the research team—we look forward to hearing more at the LRI Spring Meeting.

We also thank our partner Anesvad Foundation for supporting this important work, and El País for its insightful reporting that helps bring visibility to these critical issues.

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/a884f4d4-a50c-465e-809a-c1682bc0b43fn%40googlegroups.com.

Fw: Ref.: (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 129, December 2025

 

Leprosy Mailing List �C   January 21,  2026

 

Ref.:  (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 129, December 2025

From: Takahiro NANRI, Tokyo, Japan

____________________________________________________________________________

 

Dear Dr. Schreuder and Friends,  

 

Warm greetings from Sasakawa Health Foundation/ Sasakawa Leprosy (Hansen's Disease) Initiative in Tokyo.

We have issued WHO Goodwill Ambassador's Leprosy Bulletin NO.129 December 2025 "Achieving our goals with dedication and compassion." In this issue, we feature: 

 

MESSAGE FROM THE AMBASSADOR
On Nov. 28, 2025, I met with the 14th Dalai Lama for the first time in 11 years. The year before that last meeting, in 2013, we visited one of India's approximately 750 leprosy colonies together. His Holiness was moved and surprised me by offering to use his own book royalties to support young people living in the colonies to pursue higher education. Read More 

 

VIEWPOINT
Empowerment cannot exist without ownership: Members of the Drafting Committee reflect on the 3rd Global Forum's outcome documents

The 3rd Global Forum of People's Organizations on Leprosy/ Hansen's Disease, facilitated by the Sasakawa Leprosy Initiative, took place July 4�C6, 2025, in Bali, Indonesia. More than 110 representatives of organizations of persons affected by leprosy from 21 countries participated. Read more

 

VIEWPOINT
Persons affected by leprosy research stigma and discrimination in India and Brazil

Ashutosh Prabhavalkar, Head of Program (Leprosy),  ALERT-India

Francilene Carvalho de Mesquita Volunteer and Deputy Coordinator, Department of Policies for Women, MORHAN National Volunteer, MORHAN Piauí  

Read the article

 

AMBASSADOR'S JOURNAL

Goodwill Ambassador Sasakawa attends national conference in Sri Lanka

On Nov. 6 and 7, the Sri Lanka National Leprosy Conference "Join Hands to End Leprosy" was held at the Cinnamon Grand Hotel in Colombo.The conference was jointly organized by Sri Lanka's Ministry of Health, the Sasakawa Leprosy (Hansen's Disease) Initiative, and the World Health Organization. Sri Lanka's head of state and government, President Anura Kumara Dissanayake, attended. Read more

 

VIEWPOINT

Commentary on Global Leprosy Update 2024  
Dr. Venkata Ranganadha Rao Pemmaraju, Program Advisor for Medical Issues, Sasakawa Health Foundation

Leprosy still exists: the data from 188 countries published by the World Health Organization (WHO) as the Global Leprosy Update 2024 confirms it. As per the update, 172,717 new leprosy cases were reported from 133 countries. WHO listed 23 countries as global priority countries, which together accounted for 96% (165,578) of new cases detected during the year. Read more

 

OBITUARY
Chiemi Sanga passed away on September 20, 2025

Contributed by Dr. Takahiro Nanri, President, Sasakawa Leprosy (Hansen's Disease) Initiative
Chiemi Sanga joined the Sasakawa Health Foundation in 2012. She started in the General Affairs Department, and then, in 2017, she moved to the Leprosy Division, where she served as Chief Program Officer and Director for eight years.  She consistently played a central role in the Nippon Foundation�CSasakawa Health Foundation Joint Leprosy Program Office, established in 2018 to enable the Nippon Foundation Group to tackle leprosy more effectively. Read more

 

BACK ISSUES 

 

We hope that you would enjoy reading the latest Leprosy Bulletin. 

 

Takahiro NANRI, Ph.D.
President, Sasakawa Leprosy (Hansen's Disease) Initiative

*********************************************************
Sasakawa Leprosy (Hansen's Disease) Initiative
Sasakawa Health Foundation
Tel：81-3-6229-5377, Fax：81-33-6229-5388
email: hansen@shf.or.jp

*********************************************************

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/7c6f189e-e2e3-4b81-9460-a15258601bffn%40googlegroups.com.

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. December 2025

 

 

Leprosy Mailing List –  January 14,  2026

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy. December 2025

From: Elizabeth Talatu Williams, Amsterdam, the Netherlands

____________________________________________________________________________

Dear colleagues,

As we step into a new year, we are delighted to welcome you back and, slightly behind schedule, share the December 2025 edition of the Infolep Newsletter. We hope you had a restful and refreshing holiday season, and we wish you a healthy, successful, and fulfilling year ahead.

This special edition brings together a robust collection of research, case studies, and global perspectives on leprosy and related conditions. From community empowerment initiatives in Nepal and progress toward Zero Leprosy, to epidemiological insights from Africa, Asia, and Latin America, this issue reflects the continued momentum, innovation, and commitment across the global leprosy community.

In addition, this issue features global news and upcoming events for 2026, including the International Conference on Economic Inclusion for Persons with Disabilities in Dhaka and the 51st Topics in Infection meeting in London, offering important opportunities for learning, collaboration, and advocacy in the year ahead.

Looking ahead to 2026, we remain inspired by your dedication to research, care, advocacy, and elimination efforts. We hope this edition provides valuable insights, sparks new ideas, and supports your important work in the months ahead.

Thank you for being part of the Infolep community. We look forward to another year of knowledge sharing, collaboration, and impact.

Please feel free to contact us if you would like access to full-text versions that are not available on Infolep, or if you would like our support with literature searches.

Warm wishes for a successful year ahead.
Elizabeth Talatu Williams

www.leprosy-information.org
info@infolep.org
 

 

 

Featured Research Spotlight

Fostering empowerment: Transition from self-help groups to cooperatives in leprosy-affected communities in Nepal
Shrestha D, Shrestha B, Ansari S, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (12): 1-22. 

---

Zero leprosy is within reach: eliminating leprosy in low-endemic settings demands political will
Fastenau A. The Lancet Regional Health - Southeast Asia. Elsevier BV. 2026.

---

Epidemiology and Clinical Characteristics of Leprosy Patients at Mankweng Hospital, Limpopo Province, South Africa
Sema-Ramashala AR, Mavhungu R, Lekoloana MA. FHS Research Day 2025. MDPI. 2025. 

---

Leprosy in Brazil: historical trajectory, advances, and epidemiological challenges in the context of social inequalities
Costa ALP, Siqueira RL, dos Santos VDS, et al. Health Sciences - 3° Edição. Seven Editora. 2025. 

---

Strengthening leprosy control through capacity building of allied health workers: A pre–post design
Mohan R, Mary JJF, Balaji R, et al. Journal of Family Medicine and Primary Care. Ovid Technologies (Wolters Kluwer Health). 2025; 14 (11): 4738-4743. 

---

Toward Indonesia's Zero Leprosy 2030: Key Lessons from Epidemiological Trends in Papua 2020 - 2024
Sumolang I, Romadhon D, Suyanto A. Folia Medica Indonesiana. 2025; 61 (1): 128-138.

---

Temporal trends and identification of risk areas related to the burden of leprosy in Brazil: an ecological study from 2001 to 2021
Da Paz WS, dos Reis ES, Bezerra-Santos M, et al. Clinical and Experimental Dermatology. Oxford University Press (OUP). 2025.

---

Analysis of the Spatial Distribution of New Cases of Leprosy in the State of Pernambuco, Northeast Brazil
Barbosa CC, Bezerra GSN, Xavier AT, et al. Tropical Medicine and Infectious Disease. MDPI AG. 2025; 10 (12): 1-18.

---

Therapeutic failure of multidrug therapy for leprosy: A retrospective case series in a hyperendemic Brazilian City
Fonseca AMFDA, Rosa PS, Belone ADFF, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (11): 1-20.

---

Co-developing strategies for leprosy management in Malaysia: A transdisciplinary research approach involving individuals affected by leprosy and other stakeholders
Abdul Rahman N, Rajaratnam V, Peters RM, et al. Global Public Health. Informa UK Limited. 2025; 20 (1): 1-17.

---

Participatory construction of an assistive technology for leprosy contact surveillance
Duarte BAS, Nogueira LMV, Jesus HGD, et al. Revista Brasileira de Enfermagem. FapUNIFESP (SciELO). 2025; 78 (suppl 4): 1-9.

 

 

 

Other New publications

Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.

 

Assessment of quality of life of patients with leprosy treated at a tertiary care centre in western Maharashtra
Ray AK, Tripathi S, Ali HHA, et al. International Journal Of Community Medicine And Public Health. Medip Academy. 2025; 12 (12): 5640-5644. 

---

Associated Factors of Mycobacterium Leprae Infection among People with Leprosy in Kwale County
Karani V, Dierro L, Rono A, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2025; 19 (11): 1-13.

---

Factors associated with non-adherence to polychemotherapy treatment for leprosy.
Johnne da Cruz, Eliane Franchi. Revista brasileira de enfermagem. 2025; 78 (4): 1-10.

---

Expanding the Genetic Insights Into Leprosy: An Updated Meta-Analysis of Interleukin-10 Variants.
Veeraraghavan J, Stephen S, Narasimhan M, et al. International journal of immunogenetics. 2025.

---

Self-assessment of risk of dysphagia and clinical-functional vulnerability in older adults with a history of leprosy
Rocha MC, Mourão AM, Jesus JDSD, et al. CoDAS. FapUNIFESP (SciELO). 2025; 37 (6): 1-8. 

---

Transmission Patterns and Factors Influencing High Incidence of Leprosy among Indigenous Penan in Sarawak, Malaysia
Maurice Steve Utap, Chirk Jenn Ng, Yew Kong Lee, et al. Journal of Community Health. 2025.

---

A study of correlation between anxiety and depression of leprosy patients
Dr. Rajendra Patel. International Education & Research Journal (IERJ). 2025; 11 (12): 5-7. 

 

Optimizing treatment of lepromatous form of leprosy using ofloxacin on top of standard multi-drug therapy in National Referral Hospital, Jakarta, Indonesia.
Priyanto M, Yunifananda M, Menaldi S, et al. F1000Research. 2025.

---

Leprosy elimination: are we winning the fight or losing focus?
Edward M, Owoicho AW. Annals of Medicine. Informa UK Limited. 2025; 57 (1): 1-9. 

---

The Effect of Health Education on Leprosy-Related Stigma Among Patients and Family Contacts at Prof. Dr. I.G.N.G. Ngoerah General Hospital: A Pre- and Post-Study
Luh Putu Sustiana Kartika Sari , N. L. P Ratih Vibriyanti Karna , Luh Made Mas Rusyati . JOURNAL OF BIOMEDIKA AND HEALTH. 2025; 8 (3) : 1-2.

---

Assess The Lived Experiences, Overall Stigma And Quality Of Life Among People Affected With Leprosy Of Selected District East Champaran, Bihar
Ms. Pooja Kumari, Dr Priyanka Chaudhary, Mrs Babita Kumari, et al. Journal for Re Attach Therapy and Developmental Diversities. 2025; 8 (1): 181-186.

---

Rare multisystemic complications with delayed diagnosis in two cases of leprosy
Khallouki M, Bendaoud L, Serghini S, et al. Our Dermatology Online. Our Dermatology Online. 2025.

---

Molecular Viability Assay: Improving Leprosy Diagnosis beyond Current Gold Standard
Clara Imaniar, Ibnu Agus Ariyanto, Yeva Rosana. Eksakta: Berkala Ilmiah Bidang MIPA. 2025; 26 (4): 456-467.

 

 

 

 

Case Reports

A Rare Occurrence of Lepra Type II Reaction in Pure Neuritic Leprosy: A Case Report
Asfaw N, Gebrewold AM. Springer Science and Business Media LLC. 2025.

---

Chronic Anterior Uveitis in A Patient with Treated Leprosy: A Case Report
Azib S, Nejjar Y, Achegri Y, et al. Scholars Journal of Medical Case Reports. SASPR Edu International Pvt. Ltd. 2025; 13 (10) : 2305-2306. 

---

Orofacial Granulomatosis Masquerading as Borderline Tuberculoid Leprosy – A Rare Case Report
Sanchita Singha , Nitin Chaudhari , Swapna Sheth . Medical Journal of Basic and Applied Research. 2025; 5 (1): 1-3.

---

Borderline Lepromatous Leprosy Simulating Sarcoidosis on Histopathology: A Case Report.
Vashisht K, Sahni K, Singh A. Journal of cutaneous pathology. 2025.

---

A Case Report:Cutaneous Leishmaniasis Mimicking Leprosy in an Immunocompetent Young Adult: A Diagnostic and Therapeutic Challenge in the old world
Albajori R, AlHader H, ALshawa K. JAAD Case Reports. Elsevier BV. 2025.

---

From Nerves to Nodules: A Case-Based Review of the Progression of Pure Neuritic Leprosy to Lepromatous Leprosy With Erythema Nodosum Leprosum
Choubey S, Kar HK, Behera D. Cureus. Springer Science and Business Media LLC. 2025.

---

Erythema Nodosum Leprosum Triggered by Herpes Simplex Infection: A Case Report
Usamah Al-Anbagi, Abdulqadir J Nashwan, Samir Al Hyassat, et al. Cureus. Springer Science and Business Media LLC 2025.

---

Beyond the surface: Distinguishing leprosy from fungal mimics - A case report.
Jamani N, Ismail N, Shairah M. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia. 2025.

 

 

News & Events

 

 

First Croatian leprosy case in 32 years confirmed [Learner News]

---

Leprosy reported in Leon County, 36th case in Florida this year [Tallahassee Democrat]

---

TN health officials push for early mental health support for leprosy, tuberculosis patients [The New Indian Express]

---

Lepra's 'Giving Shoesday' is helping to restore dignity and hope for people affected by leprosy [Charity Today]

---

Youth with disabilities and leprosy must be centered in rural development, Experts stress [Dhaka Tribune]

---

Group tackles leprosy spread in Nasarawa communities [Punch]

---

Leprosy Mission Nigeria Laments 'Children With Disabilities Invisible In Nigeria's Budgets' [Sahara Reporters]

---

Caribbean health workers unite to accelerate leprosy elimination efforts [Pan American Health Organization]

---

Vadodara Health Department Launches Extensive Door-to-Door Leprosy Search Campaign [English Loktej]

---

Romania Confirms First Leprosy Case in Over 40 Years [Romania Journal]

---

Study looks at migrant-linked trans­mis­sion of lep­rosy in city [Press Reader]

---

Mangaluru mourns Dr Derek A. Lobo, global public-health leader and leprosy expert [News Karnataka]

---

Ernakulam reports 35 leprosy cases under treatment as state targets eradication by 2030 [The Times of India]
 

 

Launch Of Skin Health Camp In Anse La Raye [Observer News]

---

International Conference on Economic Inclusion for Persons with Disabilities
Date and Location: 18^th-19^th January, 2026, Dhaka, Bangladesh
The International Conference on Economic Inclusion for Persons with Disabilities will bring together academics and practitioners working on disability and economic inclusion, as well as people with disabilities and their representative organisations, policymakers, and donors.
Abstract submission deadline: 31 October 2025
Registration deadline: 4 January 2026

---

51st Topics in Infection
Date and Time: 30 January, 8:30AM - 6:30PM GMT
Location: Goodenough College, London House, Meckleburgh Square, London WC1N 2AB
This annual one-day meeting, is delivered as a partnership between RSTMH, Barts Health and the UK Health Security Agency. It will bring together microbiologists, infectious disease physicians, infection control personnel and biomedical and clinical scientists to hear updates on recent "hot topics" in all aspects of infectious disease. Registration is open!

---

2nd International Conference on Tropical Dermatology 11th to 14th March, 2026
Date and Location: 11th- 14th March, 2026, Colombo, Srilanka
The second International Conference on Tropical Dermatology (ICTD), which will be held at the Shangri-La Hotel in Colombo. This esteemed event is co-organized by the Sri Lanka College of Dermatology and Aesthetic Medicine (SLCDA) in collaboration with the Deutsche Dermatologische Gesellschaft / German Dermatological Society (DDG). 

 

 

 

 

Links

 

Info Hansen - An innovative hub for knowledge sharing about Hansen's Disease
 

---

ALLF - Official website of the Association des Léprologues de Langue Française
 

---

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 

---

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

 

ILEP newsletter archive

---

GPZL newsletter subscription

---

WHO Goodwill Ambassador's Leprosy Bulletin

---

Leprosy Review

---

Leprosy Review Repository (1928-2001)

---

Fontilles Revista de Leprología

---

Indian Journal of Leprosy

---

Hansenologia Internationalis

---

HARP -  Hansen's Disease Antimicrobial Resistance Profiles

 

GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can update your preferences or unsubscribe from this list at any time.

 

Send us an email

 

Visit our website

 

Facebook

 

Twitter

 

___________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/f2c5b7c4-0470-4947-9a0c-fc84354b41d1n%40googlegroups.com.